Health & Biotech
ASX Health Stocks: GTG set to jump into online after buying ecommerce outfit AffinityDNA
Health & Biotech
PharmAust set for Phase 1 Motor Neurone Disease trial as Monepantel tablets arrive
Health & Biotech
ASX Health Stocks: Cancer fighter Amplia will start Phase 2 trial after getting final ethics approval
Health & Biotech
Stock Insiders: NGS are reaching new heights with a clinically tested nutritional supplement
Health & Biotech
Incannex shares reach a high of 44c on landmark $125m deal to buy US cannabinoid pioneer APIRx
Health & Biotech
ASX Health Stocks: Race and Rhythm make their moves to advance Australian share
Health & Biotech
Check Up: Is biotech a good investment in a higher rate cycle? Turns out theory is just a theory
Health & Biotech
PharmAust expands canine trial of Monepantel to the US, expediting the close out of Phase 2 study
Health & Biotech
ASX Health Stocks: Integral goes big in Queensland, Credit Suisse says it’s time to choose between HLS and ACL
Health & Biotech
Bone specialist Osteopore secures key ANZ distribution as it targets oral & maxillofacial surgery
Health & Biotech
Knocking heads: Incannex achieves key concussion breakthrough
Health & Biotech
ASX Health Stocks: Ecstasy for Emyria in MDMA trial, Beamtree wins US$7m deal
Featured Health & Biotech Stocks
Health & Biotech
Healthcare stocks are as varied as the solutions they are working to solve. The sector covers biotech stocks developing breakthrough pharmaceutical drugs and vaccines to medtech companies launching the latest and greatest medical devices they hope will change the face of healthcare.
Even the ‘budding’ medical cannabis industry is in the mix as researchers explore new applications and treatments.
If you want to know what’s happening with emerging health stocks on the ASX, Stockhead has you covered, with daily stock news, expert insight and research. You can also recap broader industry trends and recent share price movements across the sector in our regular ‘Check Up’ feature.
Accurate, up-to-date news stories are important, especially in the health sector where progress is often slow and risk often high. That’s why we’re focused on helping small cap investors make sense of the medical jargon.